The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Making millions through the stock market is only possible in a few ways. Investors need one of these three things: Massive sums of capital to begin with Decades of time and more modest sums of capital...
- Investigator-initiated study includes leading researchers in SCD gene therapy clinical development from St. Jude Children's Research Hospital, Inc. and two other clinical sites - - New trial to ...
BioLineRx Ltd. (NASDAQ:BLRX ) Q1 2024 Earnings Call Transcript May 28, 2024 8:30 AM ET Company Participants John Lacey - Head of IR and Corporate Communications Phil Serlin - CEO Holly May - President...
- Steady growth in APHEXDA ® adoption in first full quarter post-approval - - Among top 80 transplant centers, secured APHEXDA formulary placement to date at institutions representing ~26% of ste...
New analysis of biopsy samples demonstrated a significant increase in CD8+ T-cell density in tumors from all 11 patients treated 7 of 11 patients in the pilot phase experienced a partial response,...
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , May 22, 2024 /PRNewswire/ -- BioLineRx Ltd....
TEL AVIV, Israel , May 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies...
- Presentation Today, Monday, May 6, 2024 in Atlanta, Georgia - TEL AVIV, Israel , May 6, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical compan...
TEL AVIV, Israel , April 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseas...